H.C. Wainwright lowers Cardiff Oncology stock price target on trial data

H.C. Wainwright lowered its price target for Cardiff Oncology (CRDF) to $10.00 from $18.00, while retaining a Buy rating, following updated CRDF-004 trial results that showed a reduced objective response rate delta for onvansertib compared to prior data and prompted a cut in the drug's probability of approval from 40% to 25%. This adjustment comes as the clinical-stage biotech reported a Q2 EPS loss of $0.21, missing analyst projections, despite revenue surpassing estimates.

Analysis

H.C. Wainwright has materially revised its outlook on Cardiff Oncology (CRDF), cutting its price target to $10.00 from $18.00 while paradoxically maintaining a Buy rating. The downgrade is directly linked to updated CRDF-004 trial data for onvansertib, which showed a diminished clinical benefit. The confirmed objective response rate delta between the combination therapy and the standard of care arm narrowed to 19% (49% vs 30%), a significant decline from the 31% delta (64% vs 33%) observed in a smaller, earlier cohort. Compounding these concerns, the analyst noted a patient imbalance in ECOG performance status, with the treatment arm having a disproportionately healthier patient population (61% ECOG 0 vs 35% in control), which may have inflated the reported efficacy. Consequently, the firm has reduced its estimated probability of the drug's approval from 40% to 25%. This clinical setback is amplified by the company's recent financial performance, where it reported a Q2 loss of $0.21 per share, missing consensus estimates of a $0.19 loss, and saw operating expenses climb to $14.9 million from $12.7 million year-over-year, indicating a rising cash burn.

Key Decisions for Investors

• Investors should re-evaluate the risk profile for CRDF, as the reduced efficacy delta and methodological concerns in the onvansertib trial have lowered its probability of approval to 25%, increasing the binary risk inherent in this clinical-stage asset.
• Monitor the company's cash burn and financing needs closely, given that operating expenses rose to $14.9 million in the last quarter and the company missed earnings per share estimates.
• Despite the negative trial update, the maintained 'Buy' rating from H.C. Wainwright suggests a potential high-risk, high-reward scenario, but at a significantly lower valuation, warranting caution and potentially smaller position sizes for risk-averse investors.